| 000 | 01704 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513214254.0 | ||
| 264 | 0 | _c20000808 | |
| 008 | 200008s 0 0 eng d | ||
| 022 | _a0021-972X | ||
| 024 | 7 |
_a10.1210/jcem.85.7.6666 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPhillips, D J | |
| 245 | 0 | 0 |
_aRelease of activin and follistatin during cardiovascular procedures is largely due to heparin administration. _h[electronic resource] |
| 260 |
_bThe Journal of clinical endocrinology and metabolism _cJul 2000 |
||
| 300 |
_a2411-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aActivins |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aAortic Aneurysm, Abdominal _xsurgery |
| 650 | 0 | 4 |
_aCardiovascular Surgical Procedures _xadverse effects |
| 650 | 0 | 4 | _aCoronary Angiography |
| 650 | 0 | 4 | _aEndarterectomy, Carotid |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollistatin |
| 650 | 0 | 4 |
_aGlycoproteins _xmetabolism |
| 650 | 0 | 4 |
_aGrowth Substances _xmetabolism |
| 650 | 0 | 4 |
_aHeparin _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInhibins _xmetabolism |
| 650 | 0 | 4 |
_aInterleukin-1 _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aJones, K L | |
| 700 | 1 | _aMcGaw, D J | |
| 700 | 1 | _aGroome, N P | |
| 700 | 1 | _aSmolich, J J | |
| 700 | 1 | _aPärsson, H | |
| 700 | 1 | _ade Kretser, D M | |
| 773 | 0 |
_tThe Journal of clinical endocrinology and metabolism _gvol. 85 _gno. 7 _gp. 2411-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1210/jcem.85.7.6666 _zAvailable from publisher's website |
| 999 |
_c10853075 _d10853075 |
||